The pathogenesis of lymphoproliferative diseases (LPD) involves a variety of complex factors leading to abnormal intracellular signal pathways and clonal formation of lymphocytes. Patients are often accompanied by a viral infection, cytogenetic abnormalities, and gene mutations. Among them, the characteristics at the genetic level will enable more accurate subtype typing, which has guiding significance for individualized treatment. The existing prognostic models based on clinical variables cannot provide a sufficiently accurate prognostic evaluation. Indeed, specialized immunophenotypes and molecular gene characteristics also have an important implication on the prognosis. The immune escape induced by multiple factors increases the difficulty of treatment, thus its mechanism is worth exploring. In addition, for some LPDs, there is still no effective individual prognostic evaluation and risk stratification system. In recent years, targeted immunotherapy, especially cell therapy, has brought revolutionary changes to the individualized treatment of LPD. Some new therapeutic drugs and new treatment technologies are constantly updated bringing hopes for curing LPD completely.
This Research Topic aims to provide a forum to promote the research on the occurrence mechanism, drug resistance, and immune escape mechanism of lymphoproliferative diseases. In addition, we look forward to studies on new prognosis evaluation systems and the exploration of novel clinical treatment for lymphoproliferative diseases, especially the clinical trials of cellular immunotherapy and prospective targeted therapies. However, purely bioinformatics papers will not be considered in this Research Topic.
Here, we welcome Original Research, Reviews, and other forward-looking research articles including, but are not limited to, the following sub-topics:
1. Pathogenesis of lymphoproliferative diseases, especially those based on signal transduction and immune regulation
2. Molecular mechanism of drug resistance and immune escape of lymphoproliferative diseases
3. Study on prognosis and risk stratification based on immune and molecular gene variables.
4. New treatment strategy or new immunotherapy technology, especially immune cell treatment, such as chimeric antigen receptor-engineered T cell (CAR-T) or T-cell receptor cell (TCR-T) treatment for lymphoproliferative diseases
5. Prospective clinical trials for lymphoproliferative diseases
The pathogenesis of lymphoproliferative diseases (LPD) involves a variety of complex factors leading to abnormal intracellular signal pathways and clonal formation of lymphocytes. Patients are often accompanied by a viral infection, cytogenetic abnormalities, and gene mutations. Among them, the characteristics at the genetic level will enable more accurate subtype typing, which has guiding significance for individualized treatment. The existing prognostic models based on clinical variables cannot provide a sufficiently accurate prognostic evaluation. Indeed, specialized immunophenotypes and molecular gene characteristics also have an important implication on the prognosis. The immune escape induced by multiple factors increases the difficulty of treatment, thus its mechanism is worth exploring. In addition, for some LPDs, there is still no effective individual prognostic evaluation and risk stratification system. In recent years, targeted immunotherapy, especially cell therapy, has brought revolutionary changes to the individualized treatment of LPD. Some new therapeutic drugs and new treatment technologies are constantly updated bringing hopes for curing LPD completely.
This Research Topic aims to provide a forum to promote the research on the occurrence mechanism, drug resistance, and immune escape mechanism of lymphoproliferative diseases. In addition, we look forward to studies on new prognosis evaluation systems and the exploration of novel clinical treatment for lymphoproliferative diseases, especially the clinical trials of cellular immunotherapy and prospective targeted therapies. However, purely bioinformatics papers will not be considered in this Research Topic.
Here, we welcome Original Research, Reviews, and other forward-looking research articles including, but are not limited to, the following sub-topics:
1. Pathogenesis of lymphoproliferative diseases, especially those based on signal transduction and immune regulation
2. Molecular mechanism of drug resistance and immune escape of lymphoproliferative diseases
3. Study on prognosis and risk stratification based on immune and molecular gene variables.
4. New treatment strategy or new immunotherapy technology, especially immune cell treatment, such as chimeric antigen receptor-engineered T cell (CAR-T) or T-cell receptor cell (TCR-T) treatment for lymphoproliferative diseases
5. Prospective clinical trials for lymphoproliferative diseases
